title: Protective effect of PACAP against doxorubicin-induced cell death in cardiomyocyte culture.
abstract: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a widely distributed endogenous neuropeptide, also occurring in the cardiovascular system. Among others, PACAP has been suggested as a cardioprotective factor. It has been shown that PACAP inhibits cardiac fibrosis and protects cardiomyocytes against oxidative stress and in vitro ischemia/reperfusion. The aim of the present study was to investigate whether PACAP is protective in doxorubicin-induced cell death of cardiomyocytes. Cardiomyocytes were exposed to 1 µM doxorubicin for 24 h, which resulted in a marked reduction of cell viability and a parallel increase of apoptotic cells assessed by MTT test and annexin V/propidium iodide flow cytometry assay. Co-incubation with 20 nM PACAP increased cell viability and reduced the percentage of apoptotic cells. Furthermore, doxorubicin increased the activation of caspase-3 and decreased the phosphorylation of Bad, while simultaneous PACAP treatment reduced the caspase-3 activation and increased the level of phospho-Bad. In summary, our present results demonstrate that PACAP effectively protects cardiomyocytes against doxorubicin-induced apoptotic cell death.
authors.affiliation: Department of Biochemistry and Medical Chemistry, University of Pecs, Szigeti u 12, Pecs, Hungary. boglarka.racz@aok.pte.hu
authors.forename: Boglarka
authors.initials: B
authors.lastname: Racz
authors.forename: Dora
authors.initials: D
authors.lastname: Reglodi
authors.forename: Gabriella
authors.initials: G
authors.lastname: Horvath
authors.forename: Andras
authors.initials: A
authors.lastname: Szigeti
authors.forename: Borbala
authors.initials: B
authors.lastname: Balatonyi
authors.forename: Erzsebet
authors.initials: E
authors.lastname: Roth
authors.forename: Gyorgy
authors.initials: G
authors.lastname: Weber
authors.forename: Nasri
authors.initials: N
authors.lastname: Alotti
authors.forename: Gabor
authors.initials: G
authors.lastname: Toth
authors.forename: Balazs
authors.initials: B
authors.lastname: Gasz
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects* / Q000502:physiology; D002478:Cells, Cultured; D004317:Doxorubicin / Q000494:pharmacology*; D006801:Humans; D032383:Myocytes, Cardiac / Q000166:cytology / Q000187:drug effects*; D018384:Oxidative Stress / Q000187:drug effects; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000737:chemistry / Q000494:pharmacology*; D020033:Protein Isoforms / Q000737:chemistry / Q000494:pharmacology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000903:Antibiotics, Antineoplastic; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D020033:Protein Isoforms; D004317:Doxorubicin
references.citation: Circulation. 2004 Nov 16;110(20):3245-51
references.pmid: 15520307
references.citation: Ann N Y Acad Sci. 2006 Jul;1070:293-7
references.pmid: 16891268
references.citation: Acta Histochem. 2009;111(2):93-103
references.pmid: 18805572
references.citation: Regul Pept. 2005 Jul 15;129(1-3):139-46
references.pmid: 15927709
references.citation: Regul Pept. 2003 Feb 28;110(3):179-88
references.pmid: 12573798
references.citation: Am J Physiol Heart Circ Physiol. 2001 Mar;280(3):H1058-65
references.pmid: 11179047
references.citation: Neuroscience. 2005;134(3):745-56
references.pmid: 16019148
references.citation: Ann N Y Acad Sci. 2009 Apr;1163:512-6
references.pmid: 19456402
references.citation: Biochem Biophys Res Commun. 2009 Oct 30;388(4):727-31
references.pmid: 19699179
references.citation: Neurotox Res. 2007 Sep;12(2):95-104
references.pmid: 17967733
references.citation: Semin Oncol. 1992 Dec;19(6):670-86
references.pmid: 1462166
references.citation: J Mol Neurosci. 2008 Nov;36(1-3):292-8
references.pmid: 18509761
references.citation: Eur J Neurosci. 2000 Jul;12(7):2243-51
references.pmid: 10947803
references.citation: Clin Exp Pharmacol Physiol. 2003 Dec;30(12):937-42
references.pmid: 14678233
references.citation: J Pharmacol Exp Ther. 2010 Feb;332(2):413-20
references.pmid: 19915070
references.citation: Neurotox Res. 2009 Jan;15(1):24-37
references.pmid: 19384585
references.citation: Neuroscience. 2004;126(2):335-46
references.pmid: 15207351
references.citation: Regul Pept. 2009 Jan 8;152(1-3):33-40
references.pmid: 18682263
references.citation: Ann N Y Acad Sci. 2000;921:55-67
references.pmid: 11193880
references.citation: Peptides. 2001 Nov;22(11):1859-66
references.pmid: 11754973
references.citation: J Mol Neurosci. 2008 Nov;36(1-3):26-37
references.pmid: 18506634
references.citation: Curr Pharm Des. 2004;10(23):2861-89
references.pmid: 15379674
references.citation: Pediatr Res. 1993 Sep;34(3):323-8
references.pmid: 7510869
references.citation: Regul Pept. 2002 Nov 15;109(1-3):107-13
references.pmid: 12409222
references.citation: Gen Comp Endocrinol. 2007 Aug-Sep;153(1-3):115-23
references.pmid: 17270184
references.citation: Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1233-7
references.pmid: 18637020
references.citation: Eur J Pharmacol. 2008 Feb 26;581(1-2):47-53
references.pmid: 18154951
references.citation: Regul Pept. 2010 Feb 25;160(1-3):91-8
references.pmid: 19969027
references.citation: Br J Pharmacol. 2003 Jul;139(5):1050-8
references.pmid: 12839880
references.citation: Brain Res. 2007 Aug 24;1165:81-8
references.pmid: 17658492
references.citation: Pharmacol Rev. 2009 Sep;61(3):283-357
references.pmid: 19805477
references.citation: Endocrinology. 1999 Feb;140(2):818-26
references.pmid: 9927311
references.citation: Am J Pathol. 1999 Dec;155(6):1893-900
references.pmid: 10595920
references.citation: Brain Res. 2009 Aug 4;1283:50-7
references.pmid: 19538945
references.citation: Mol Cell Neurosci. 2006 Mar;31(3):586-95
references.pmid: 16431129
references.citation: Regul Pept. 1993 Sep 3;47(2):213-20
references.pmid: 7901874
references.citation: J Immunol Methods. 1995 Jul 17;184(1):39-51
references.pmid: 7622868
references.citation: Regul Pept. 2008 Jan 10;145(1-3):105-15
references.pmid: 17981349
references.citation: Acta Pharmacol Sin. 2009 Nov;30(11):1479-87
references.pmid: 19890356
references.citation: Am J Cardiovasc Drugs. 2002;2(1):43-57
references.pmid: 14727998
references.citation: J Vasc Res. 1997 Jan-Feb;34(1):11-8
references.pmid: 9075821
references.citation: Free Radic Biol Med. 2008 Dec 15;45(12):1723-8
references.pmid: 18926904
references.citation: Peptides. 2006 Jan;27(1):87-94
references.pmid: 16095757
references.citation: Eur J Pharmacol. 1994 Apr 15;267(2):195-206
references.pmid: 7519562
references.citation: Brain Res. 2000 Nov 3;882(1-2):180-90
references.pmid: 11056197
references.citation: J Mol Neurosci. 2008 Nov;36(1-3):8-15
references.pmid: 18574733
references.citation: J Mol Neurosci. 2008 Nov;36(1-3):105-14
references.pmid: 18473188
references.citation: Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13390-5
references.pmid: 11087878
references.citation: J Mol Neurosci. 2005;27(1):91-105
references.pmid: 16055949
references.citation: Drug News Perspect. 2005 Jul-Aug;18(6):387-91
references.pmid: 16247516
references.citation: FEBS Lett. 2005 Jul 18;579(18):4005-11
references.pmid: 16004991